trending Market Intelligence /marketintelligence/en/news-insights/trending/zn1yjhpmabgzbplbrti3uw2 content esgSubNav
In This List

Santhera completes CHF23.5M accelerated bookbuild offering

Video

According to Market Intelligence, December 2022

Blog

Insight Weekly: Layoffs swell; energy efficiency PE deals defy downturn; 2023 global risk themes

Blog

Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook

Blog

Japan M&A By the Numbers: Q3 2022


Santhera completes CHF23.5M accelerated bookbuild offering

Santhera Pharmaceuticals Holding AG completed a share placement offering to raise about CHF23.5 million in gross proceeds to fund a pending drug licensing deal with Idorsia Ltd.

The Swiss specialty pharmaceutical company placed a total of 3,133,334 shares in the offering at CHF7.50 apiece. Santhera's share capital will increase from about CHF7.5 million to CHF10.7 million as a result of the transaction.

Santhera plans to use $20 million of the net proceeds to pay the cash component of a pending deal with Idorsia to license the steroid vamorolone. The payment will complete that transaction. Vamorolone is a steroid seen as a safer alternative for patients with Duchenne muscular dystrophy.

The company expects the shares to start trading on the SIX Swiss Exchange around Dec. 18.